CA3038845C - Methods for treating ocular diseases - Google Patents

Methods for treating ocular diseases Download PDF

Info

Publication number
CA3038845C
CA3038845C CA3038845A CA3038845A CA3038845C CA 3038845 C CA3038845 C CA 3038845C CA 3038845 A CA3038845 A CA 3038845A CA 3038845 A CA3038845 A CA 3038845A CA 3038845 C CA3038845 C CA 3038845C
Authority
CA
Canada
Prior art keywords
compound
diabetic
cells
bmx
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3038845A
Other languages
English (en)
French (fr)
Other versions
CA3038845A1 (en
Inventor
George Chung-Yih Chiou
Chia-Nan Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelwise Pharmaceutical Corp
Original Assignee
NatureWise Biotech and Medicals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NatureWise Biotech and Medicals Corp filed Critical NatureWise Biotech and Medicals Corp
Publication of CA3038845A1 publication Critical patent/CA3038845A1/en
Application granted granted Critical
Publication of CA3038845C publication Critical patent/CA3038845C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3038845A 2016-09-29 2017-09-29 Methods for treating ocular diseases Active CA3038845C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401725P 2016-09-29 2016-09-29
US62/401,725 2016-09-29
PCT/CN2017/104345 WO2018059543A1 (en) 2016-09-29 2017-09-29 Methods for treating ocular diseases

Publications (2)

Publication Number Publication Date
CA3038845A1 CA3038845A1 (en) 2018-04-05
CA3038845C true CA3038845C (en) 2022-04-19

Family

ID=61688114

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3038845A Active CA3038845C (en) 2016-09-29 2017-09-29 Methods for treating ocular diseases

Country Status (9)

Country Link
US (1) US11045435B2 (https=)
EP (1) EP3518913B1 (https=)
JP (3) JP2019531296A (https=)
KR (1) KR102341446B1 (https=)
CN (1) CN109789115A (https=)
CA (1) CA3038845C (https=)
MY (1) MY198731A (https=)
TW (1) TWI765917B (https=)
WO (1) WO2018059543A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585196B (zh) * 2018-06-13 2022-11-04 郭涛 一种治疗及预防眼科疾病的药物及其应用
KR20240016352A (ko) * 2021-05-28 2024-02-06 노벨와이즈 파마슈티칼 코포레이션 약물-내성 암을 치료하기 위한 조성물 및 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
JP4873904B2 (ja) * 2005-08-22 2012-02-08 国立大学法人弘前大学 眼血管血流障害改善剤
EP2135620A4 (en) 2007-03-28 2010-12-29 Santen Pharmaceutical Co Ltd AGAINST OKULAR HYPOTONIA CONNECTED TO HISTONE DEACETYLASE INHIBITION AS AN ACTIVE SUBSTANCE
CA2630174A1 (en) * 2007-05-02 2008-11-02 Mitchell Alan Winnik Loading quantum dots into thermo-responsive microgels by reversible transfer from organic solvents to water
US20110014294A1 (en) 2008-03-03 2011-01-20 Pharmalight Inc. Stimulation of ocular retrobulbar blood flow using ocular irritants
EP2346827B1 (en) * 2008-08-27 2013-11-13 Leo Pharma A/S Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
ES2473792T3 (es) * 2009-04-03 2014-07-07 Naturewise Biotech & Medicals Corporation Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
EP2277387B1 (en) * 2009-07-22 2016-10-19 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly
CN104080467B (zh) * 2011-05-09 2020-09-15 急速制药公司 整联蛋白受体拮抗剂及其使用方法
CA2946086A1 (en) * 2014-04-17 2015-10-22 Teraclon Idf, S.L. Recombinant monoclonal antibodies vnar neutralizing the vascular endothelial growth factor (vegf)
US9956254B2 (en) * 2015-02-26 2018-05-01 Naturewise Biotech & Medicals Corporation Extract of taiwanese propolis for treating ocular diseases

Also Published As

Publication number Publication date
JP2019531296A (ja) 2019-10-31
KR20190045304A (ko) 2019-05-02
JP2021138710A (ja) 2021-09-16
CA3038845A1 (en) 2018-04-05
US20180085329A1 (en) 2018-03-29
EP3518913A1 (en) 2019-08-07
TW201828933A (zh) 2018-08-16
EP3518913C0 (en) 2025-07-23
WO2018059543A1 (en) 2018-04-05
EP3518913A4 (en) 2020-05-27
US11045435B2 (en) 2021-06-29
CN109789115A (zh) 2019-05-21
MY198731A (en) 2023-09-20
KR102341446B1 (ko) 2021-12-21
TWI765917B (zh) 2022-06-01
JP2023116748A (ja) 2023-08-22
EP3518913B1 (en) 2025-07-23

Similar Documents

Publication Publication Date Title
Moran et al. Protective and antioxidant effects of PPARα in the ischemic retina
Ko et al. Dynamic changes in reactive oxygen species and antioxidant levels in retinas in experimental glaucoma
Sivak The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease
Liang et al. Salidroside alleviates oxidative stress in dry eye disease by activating autophagy through AMPK-Sirt1 pathway
Wang et al. Erythropoietin protects retinal pigment epithelial cells from oxidative damage
CN108348781B (zh) 用于治疗与线粒体活性氧簇(ros)产生相关的疾病的化合物
Fu et al. Neuroprotective effect of apigenin against hypoxic-ischemic brain injury in neonatal rats via activation of the PI3K/Akt/Nrf2 signaling pathway
AU2018334467B2 (en) Method and improved neuroprotective composition for treating neurological conditions
TW201038544A (en) Anti-neurodegenerative diseases agents
Yang et al. Highly effective corneal permeability of reactive oxygen species-responsive nano-formulation encapsulated cyclosporine a for dry eye management
US9694010B2 (en) Therapeutic formulation and methods of treatment
JP2023116748A (ja) 眼疾患の処置方法
JP7436067B2 (ja) ナノ低分子ペプチドｆｇ及びその眼底血管疾患の治療用薬物又は予防用薬物の調製への使用
CA2554679C (en) Prophylactic or therapeutic agent for diabetic maculopathy
Mei et al. Linarin ameliorates innate inflammatory response in an experimental dry eye model via modulation of the NLRP3 inflammasome
CN105343107A (zh) 雷公藤红素在制备防治视网膜退行性改变相关疾病药物中的应用
KR102642795B1 (ko) 망막 질환을 치료하기 위한 미라베그론
Jia et al. Edaravone promotes motoneuron survival and functional recovery after brachial plexus root avulsion and reimplantation in rats: Involvement of SIRT1/TFEB pathway
EP3380194B1 (en) Composition for blocking angiogenesis
HK40002019A (zh) 用於治疗眼疾的方法
Chen et al. Neuroprotective Effects of the SIRT3/AMPK Axis in Experimental Glaucoma
Sarkis¹ et al. Challenging glaucoma with emerging therapies: an overview of advancements against the
KR102068697B1 (ko) 염증성 안구표면질환의 예방 또는 치료용 조성물
Shen et al. Permeable nanoreactor eye drop for enzymatic cascade-mediated treatment for acute retinal injury model mimicking geographic atrophy
JP6386713B2 (ja) 脳循環障害の予防剤および／または治療剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190329

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - SMALL

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240920

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240920

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240920

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - SMALL

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250919

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250919